The results showed that the mRNA expression levels of SUMO1/2/3 in 22 kinds of tumor tissues, including PAAD, stomach adenocarcinoma (STAD), and breast invasive carcinoma (BRCA), were higher than the levels in the corresponding non-tumor tissues, while the mRNA expression levels in kidney chromophobe (KICH) and acute myeloid leukemia (LAML) were lower than those in the corresponding non-tumor tissues (Figures 1A–C). This evidence concerns the gene SUMO1 and invasive breast carcinoma.